Candriam S.C.A. Beam Therapeutics Inc. Transaction History

Candriam S.C.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$17.69 - $30.76 $1.47 Million - $2.55 Million	83,000 Added 64.01%	212,665 $5.79 Million
Q2 2023 Aug 08, 2023	BUY	$29.32 - $35.99 $1.47 Million - $1.8 Million	50,000 Added 62.76%	129,665 $4.14 Million
Q2 2022 Aug 03, 2022	BUY	$29.86 - $62.36 $75,187 - $157,022	2,518 Added 3.26%	79,665 $3.08 Million
Q2 2021 Jul 20, 2021	BUY	$64.12 - $128.71 $4.95 Million - $9.93 Million	77,147 New	77,147 $9.93 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.